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WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? 18 
 First-trimester ultrasound is commonly used to detect/diagnose fetal malformations. 19 
Lately, an effort is being made to bring anatomical ultrasound from second-trimester 20 
to first-trimester. 21 
 Fetal malformations have their timing to be detected, and first-trimester ultrasound 22 
alone may not be enough to accomplish that. 23 
 24 
 25 
 2 
WHAT DOES THIS STUDY ADD? 26 
 Last years, technological and human improvements have empowered first-trimester 27 
ultrasound, which explains the need to know if its accuracy to detect/diagnose 28 
malformations earlier increased or not, and its real usefulness. 29 
 30 
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ABSTRACT 32 
Before the late nineties, ultrasound (US) was somewhat useless, mainly due to technological 33 
limitations. Only after enhancements in US instrumentation and operator skills, US began to 34 
be considered a first-line screening exam to evaluate gestation during first-trimester. 35 
Furthermore, currently the last developments are allowing handling during first-trimester 36 
tasks characteristically related to the second-trimester US, such as looking for fetal 37 
malformations. This time shift raise up a question. Is first-trimester US an accurate mean of 38 
detecting fetal malformations, which are characteristically time dependent? 39 
With this systematic review we intend to assess first-trimester US, and to quantify the US 40 
improvements in the detection rate of major structural malformations in chromosomally 41 
normal fetuses. To accomplish that we have obtained references from the MEDLINE database 42 
and analyzed 227.955 fetuses, gathered from 21 studies. Our study suggest that first-trimester 43 
US, as a tool for prenatal diagnosis of structural anomalies has potential to evolve since 44 
currently, detection rate is around 50%; however we believe that such value may be improved 45 
with the standardization of detection protocols, the concomitant use of appropriated markers 46 
and better equipment. 47 
Despite all, first-trimester fetal malformation screening still represents a diagnostic challenge 48 
in modern obstetrics.49 
 4 
INTRODUCTION 50 
In the last decade, it was estimated that fetal malformations ranged 1%–3% of all births, and 51 
constituted the most common cause of infant mortality. Most malformations are of unknown 52 
etiology, for which the only risk factor is the pregnancy itself. Hence, in this review and 53 
according to the literature, we adopted the term malformation to represent any structural 54 
anomaly, including dysmorphologies
1
, independently of the etiology. Moreover, according to 55 
the European Surveillance of Congenital Anomalies
2
 (EUROCAT) a malformation can be 56 
minor or major. Major malformations, if not lethal, comprehend all severe handicap that 57 
usually require therapeutic termination of pregnancy, and are the focus of this review. 58 
During pregnancy malformations evolve until they reach a critical state of development, 59 
which allows the detection by US. The detectability time varies according to the type of 60 
malformation, the technical features of the equipment, and the skills of the technician who is 61 
in charge of the procedure. Until not long ago, these features favored the anatomical US to be 62 
performed between the 18–22th weeks of pregnancy. 63 
However, since 80% of major malformations are present at 12 weeks of pregnancy and 64 
considering the evolution of equipment, the improvement of practitioner’s skills, and the 65 
deeper knowledge about the embryo development
3
, abnormality detection is being pulled 66 
from the second to first-trimester. 67 
The accuracy and performance of first-trimester scan is being evaluated by several studies. 68 
Detection rates ranging between 17% and 90% are referred in the literature
4–6
, and several 69 
causes have been claimed to explain such variability. The inclusion criteria defined for each 70 
study and the type and length of follow-up are pointed as having the major impact on results.  71 
As far as we know, only two papers aimed to review the data from different studies about the 72 
detection rate of first-trimester US. Nonetheless, both present some limitations.  The one from 73 
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Borrell et al.
7
 only includes 5 studies, and the one from Syngelaki et al.
8
 approaches the 74 
malformations as cardiac and non-cardiac, which is very strict in our point of view. 75 
Hence, this systematic review intends to include all eligible studies presenting major 76 
malformations in euploid fetuses, in order to evaluate the sensitivity of first-trimester US. 77 
 78 
METHODS 79 
Search strategy and eligibility criteria 80 
Studies were retrieved from a search in MEDLINE database, restricting the search to English 81 
references, using the following MeSH terms and keywords: ultrasonography, ultrasonics, 82 
ultrasound, pregnancy first trimester, first trimester, sensitivity, specificity, abnormalities, 83 
congenital abnormalities, anomalies, malformations, and detection. 84 
Further keywords were tried when defining the query. However, since they did not enhance 85 
the sensitivity of the search, they were not considered in the final query. The last search was 86 
performed on November 28, 2012. 87 
The references of each eligible study were screened for possible missing articles. None of the 88 
publications had overlapping populations. 89 
Studies were eligible if they provided data on the detection rate of major malformations in 90 
euploid fetuses, screened by first-trimester US. Table 1 presents the inclusion and exclusion 91 
criteria defined to decide about the eligibility of each paper in our pool. 92 
The criteria were applied in two phases: first, studies were screened by title and abstract for 93 
relevance. Secondly, full papers of studies, which appeared potentially relevant, were 94 
assessed for inclusion. 95 
Data extraction 96 
For each study we recorded the name of the author, country of origin, sample size, type of 97 
population, study design, length of study, gestational age and type of follow-up. The 98 
Table 1 
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prevalence of major malformations in fetuses with normal karyotype was calculated for each 99 
study, too. We also recorded the detection rate of major malformations detected by first-100 
trimester US. In some studies this value was not available, so we had to extract the necessary 101 
information to obtain the detection rate. 102 
Quality assessment of included studies was carried out using the QUADAS
9
 tool and the 103 
criteria for assessment of risk of bias defined by Pedrosa et al.
10
, both adapted as appropriate 104 
(Table 2). 105 
This review was elaborated according to the PRISMA
11
 statement in order to ensure a 106 
transparent, complete and unbiased reporting of valuable data. 107 
 108 
RESULTS 109 
Eligible studies 110 
Of the 175 items retrieved with the electronic search, 127 were excluded when assessing the 111 
titles and abstracts. The remaining 38 papers were retrieved for screening in full text. Fifteen 112 
(15) new studies were identified through scanning of bibliographic references of included 113 
papers, performing a total of 63 (48 + 15) entries to review. As depicted in Figure 1, we 114 
further excluded 43 studies that examined major malformations out of the scope of the first-115 
trimester US and studies that did not have enough information to calculate general US 116 
sensitivity. This was the case of papers voted to a specific major malformation, such as 117 
congenital heart disease (CHD) or central nervous system (CNS) malformation, or papers that 118 
addressed specific technical issues about US examination. Hence the final data included 119 
information from 20 papers (63 - 43). 120 
Study characteristics 121 
Descriptive characteristics of each eligible study are presented in Table 3. The studies have 122 
been performed in Europe, Brazil, China and Middle East, contributing with a total of 123 
Table 2 
Figure 
1 
Table 3 
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227.955 fetuses, and 3255 major malformations. Fifteen (15) were prospective cohorts, one of 124 
which cross-sectional, 2 were retrospective cohorts, 2 were reviews and 2 randomized 125 
controlled trials (RCT), which perform a total of 21 studies. In practice 20 papers were 126 
included in our review, however, the one from Syngelaki et al.
8
 presents simultaneously a 127 
prospective study and a review, both in accordance with our inclusion criteria. 128 
Among all the studies, 10 aimed at evaluating the detection rate of major malformations in 129 
euploid fetuses 
7–8, 12–19
. The studies from Hildebrand et al.
17
, Chen et al.
20
, Ebrashy et al.
21
, 130 
Saltvedt et al.
22
, Souka et al.
23
 and Öztekin et al.
24
 intended to compare the accuracy of first-131 
trimester versus second-trimester US in diagnosing major abnormalities in fetuses. Two 132 
studies were focused on evaluation of aneuploidy markers as a means to enhance first-133 
trimester US detection rate
6, 25
, and 3 studies aimed for a specific aspect of first-trimester 134 
US
26–28
. Nonetheless, all of the studies had available data in order to calculate the sensitivity 135 
of US, during first-trimester time-range. 136 
In all studies, the population was described as being low-risk, except in the paper by Chen et 137 
al.
27
, in which only women above 35 years were selected. However, as stated in the same 138 
paper, it seems that the maternal age may account for an increased number of malformations 139 
due to chromosomal abnormalities, but the same cannot be said about euploid fetuses. 140 
Risk of bias 141 
Figure 2 presents the results obtained when assessing the risk of bias, according to our 142 
modified criteria. Generally, the included studies were adequate in what concerned the 143 
selection of participants, the definition of the population, the conditions in which the 144 
screening tests were performed and the results obtained.  145 
Concerning the definition of the population, none of the studies was unclear. However, a total 146 
of 8 studies, from our pool of 21 papers, were quoted as inadequate. One (1) of them defined 147 
in its protocol a population aged more than 35 years, 2 were concerned in looking for 148 
Figure 
2 
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increased NT from an unselected population, and 1 was focused on CHD, also from an 149 
unselected population. The other main cause for an inadequate mark was the time range 150 
considered to perform the US. Six (6) studies did not respect the 11–14 weeks time range 151 
defined in our bias criteria and stated by the Fetal Medicine Foundation
29
 (FMF) as the most 152 
valuable time-range to gather first-trimester US information. Particularly, the paper by 153 
Syngelaki et al.
8
 extended its evaluation until the 16
th
 week of gestation. However, only 3 154 
fetuses were scanned at such pregnancy time.  155 
Regarding the results, the majority of the studies only presented the sensitivity of the test or 156 
had available data to calculate it (which explains the number of inadequate studies). Only a 157 
few studies presented other measures of accuracy such as specificity (2 studies) or likelihood 158 
ratios (2 studies), which is in accordance with the studies that involve US sensitivity. The 159 
majority of them present detection rate data, but only a few exhibit other measures of 160 
accuracy. 161 
With regard to the follow-up and verification, in most of the cases the number of patients that 162 
abandoned the study was not explicit, but there was enough information to calculate such 163 
value (12 papers). In 3 of them, there was not enough data. 164 
Summary of results 165 
Table 4 summarizes the results obtained from each series. It presents the number of fetuses 166 
for each study, the total of major malformations in the sample, the prevalence of major 167 
malformations, the number of malformations detected by the first-trimester US screening, and 168 
the sensitivity of the study. 169 
The lowest and highest calculated prevalences are 0.5% and 2.8%, as found in the studies of 170 
Hildebrand et al.
17
 and Becker et al.
26
, respectively. The mean value of overall studies is 1.5% 171 
(95% CI 1.2 – 1.7). Except for the lowest prevalence, all values are in the estimated range, 172 
presented by different reports, and stated above in the introduction. 173 
Table 4 
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In respect to the performance accuracy of the screen test under evaluation, sensitivity varies 174 
from 12.5% in the study of Hafner et al.
25
 and 83.7% in the study of Becker et al.
26
. Both 175 
values are out of the interval of the overall average sensitivity, 49.2% (95% CI 41.1 – 57.3), 176 
and away from the overall pooled sensitivity, 40.0% (it was not possible to calculate the 95% 177 
confidence interval due to the lack of values in all studies). 178 
 179 
DISCUSSION 180 
The findings of this systematic review on chromosomally normal fetuses revealed that first-181 
trimester US alone, as a tool to detect major structural malformations, has a moderate 182 
sensitivity. When considering pooled and averaged sensitivity the detection rate is about 183 
40.0%, and 49.2% (95% CI 41.1 – 57.3), respectively. These values slightly increase, when 184 
the two review studies are removed from the analysis group: 42.0% and 50.7%, respectively. 185 
The more significant change in the pooled average is due to the sample size of the study 186 
presented by Syngelaki et al.
8
, which involved 67.779 fetuses. 187 
Despite the moderate detection rate, we have obtained better values than the ones presented 188 
by Borrell et al.
7
 and Syngelaki et al.
8
, in their studies. For instance, some aspects may be 189 
pointed out to explain such differences. First, the number of studies included in each review, 190 
8 and 15, respectively, against our 21 studies. Moreover, in our case, from each included 191 
paper, we only have used information related to major malformations, excluding values 192 
related to minor malformations or aneuploidy. The other reviews used combined euploid, 193 
non-euploid, major and minor malformations in their results, which decrease sensitivity. 194 
Particularly, minor malformations considered in both cases, are prevalent but are hardly 195 
detected when considering first-trimester US. These outcomes strengthened our decision of 196 
evaluating first-trimester US independently of the class of malformation, since each group of 197 
malformations drifts the sensitivity of US.  198 
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Nonetheless, looking at our study that targeted US detection rate, independently of the major 199 
structural malformation, several aspects can be raised to explain why a promising detection 200 
tool revealed itself limited. 201 
Only half of the elected studies had as main goal the evaluation of first-trimester US as a tool 202 
to detect major structural abnormalities. The other half considered the detection rate by US as 203 
a secondary aspect, or did not considered such point of view at all. Moreover, the 204 
malformations aimed by each study were not the same, and it is known that US sensitivity is 205 
intrinsically connected to the malformation under evaluation. For example, Becker et al.
26
 206 
targeted cardiac defects, while Carvalho et al.
13
 looked for malformations at skull, brain, 207 
abdominal wall, with no interest in CHD. The later obtained a better US sensitivity. Also, the 208 
classification of malformations changed among studies. In some studies no classification was 209 
set down as in Weiner et al.
18
 and Hafner et al.
25
, while in other studies, specific arrangements 210 
were defined according to the purpose of the study
12–13, 23
. Besides, the detection rates 211 
presented by each study were not consistent. As reported above, the highest detection rate was 212 
achieved in the paper presented by Becker et al.
26
, while the lowest sensitivity was 12.5%, in 213 
the study of Hafner et al.
25
. Furthermore, each paper had its own protocol to evaluate first-214 
trimester US, with its own inclusion criteria and its own scanning technique. The paper 215 
presented by Chen et al.
27
 was devoted to women over 35 years of age, while the paper from 216 
Hernádi et al.
28 
intended to evaluate the transvaginal approach as a mean of enhancing the 217 
screening of fetal anatomy. 218 
External factors to the study design may also be pointed out as causes for the variance in the 219 
results, for instance, the skills of the technicians performing the US, the fetal size, the 220 
maternal habitus, etc.  221 
Regardless of the detection rate obtained, we cannot look at this study only as a number. The 222 
review presented herein intended to evaluate the sensitivity of first-trimester US for the 223 
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detection of major malformations without further considerations. Nonetheless, three aspects 224 
should always be taken into account when approaching first-trimester US: (1) the human 225 
factor; (2) the technological improvements in the detection of malformations; and (3) the 226 
malformations itself.  227 
As far as malformations are concerned, several authors have experienced in their studies
30–33
, 228 
that the part of the body system under evaluation can significantly impact on the US detection 229 
rate. For instance, sensitivity can go from less than 20%, in some cases of limb malformation, 230 
to more than 70% in some cases of CNS malformations. Considering the groups of 231 
malformations outlined by EUROCAT
2
, we present a summary of the major abnormalities 232 
that can be found using an US, and current US sensitivity. 233 
As stated before, CNS is associated with some of the malformations with the highest 234 
detection rates, and comprises about 40% of all fetal malformations
34
. Particularly, acrania 235 
and anencephaly have detection rates above 90%
37
, with an abnormal shape of the head 236 
noticeable from the 8
th
 week of pregnancy.  237 
In the opposite, hydrocephalus is rarely diagnosed in first-trimester, since dilation of 238 
ventriculus occur at a more advanced gestational stage. The same is true for agenesis of 239 
corpus callosum and microcephaly
6
. 240 
The detection of spina bifida in first-trimester US is controversial. While some studies present 241 
detection rates of 60% or more as in the study of Syngelaki et al.
8
, other studies state that 242 
spina bifida is very difficult to detect before the 14
th
 week of pregnancy, since nor the 243 
“lemon” or “banana” sign are present.  244 
Along with CNS malformations, CHD are those with the highest prevalence, and an incidence 245 
of 0.5-1/100 live born infants
35
, but one of the lower detection rates, when using US alone.  246 
The heart can be visualized since the 7
th
 week, and the four-chamber view is the conventional 247 
approach, with the following results for the most common cardiac abnormalities: 20% for 248 
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hypoplastic left heart, 10% for coarctation of the aorta, 5% for tetralogy of Fallot and 249 
ventricular septal defect and 0% for transposition of the great arteries. In order to increase 250 
detection rate, echocardiography, Doppler and soft/biochemical markers are being considered 251 
as a natural part of the fetal cardiac evaluation
7
.  252 
Abdominal wall abnormalities encompass a group of malformations, each with its own rate of 253 
detection. Omphalocele and gastroschisis can be detected more than 65% of the times
16
, as 254 
other large defects. In turn, diaphragmatic hernias, unless they are of considerable size and 255 
produce a mediastinal shift, are hardly perceived with a first-trimester US. As for cardiac 256 
malformations, the use of soft markers, such as nuchal translucency (NT) and ductus venosus 257 
(DV), may be helpful in such cases.  258 
According to Grande et al.
6
 detection rate of major urogenital tract malformations is 259 
approximately 25%. At the upper end of the spectrum are obstructive uropathies, in the form 260 
of megacystis. In the opposite extreme is renal agenesis.  261 
Fetal megacystis at 10–14 weeks of gestation, is defined by a longitudinal bladder diameter of 262 
7 mm or more, and found in about 1 in 1500 pregnancies
38
. Usually it portends a poor fetal 263 
outcome. If the longitudinal diameter of the fetal bladder is moderate (7 to 15 mm) there is a 264 
risk of about 25% of chromosomal defects. In chromosomally normal fetuses there is 265 
spontaneous resolution of the megacystis without any obvious adverse consequence on the 266 
development of the urinary system in about 90% of cases. In contrast, in megacystis with 267 
bladder diameter >15mm the risk of chromosomal defects is about 10%, but in fetuses with 268 
normal karyotype the condition is invariably associated with progressive obstructive 269 
uropathy. 270 
Renal agenesis, during first-trimester evaluation, is not characterized by oligohydramnios, and 271 
moreover kidneys are easily confused with adrenal glands, which are enlarged in this stage of 272 
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pregnancy. Then, renal agenesis is suspected when hypoechogenic masses are detected in the 273 
renal bed, which occurs less then 20% of the times. 274 
As before, when urinary malformations are suspected, it is common to have abnormal NT and 275 
DV. Moreover, the rate of detection is slightly increased if the TV route is used, when 276 
assessing the urinary tract. 277 
While minor skeletal abnormalities are more frequent than major ones, they are hardly 278 
detected in first-trimester US evaluation. Amongst the major skeletal malformations 279 
osteochondrodysplasia is the one that presents the highest detection rates in several studies
6–7
. 280 
Limbs are traditionally assessed during pregnancy as markers of fetal growth, nutrition and 281 
gestational age, and because of that, better detection rates would be expected. But it is not the 282 
case. According to the study of Rice et al.
33
, the most reported abnormalities are club hand, 283 
followed by absence of long bones, missing limb, club foot and shortening of long bones. 284 
Also important, is that most of the cases that involve limb malformations had other 285 
abnormalities associated. The most common include abdominal wall defects, single umbilical 286 
artery and hydrops. Paladini et al.
39
 described a 41% association with concomitant non-287 
chromosomal syndromic conditions and limb abnormalities.  288 
Nevertheless, as stated by Economides et al.
36
 almost all major fetal abnormalities can 289 
potentially be diagnosed in early pregnancy, if the appropriate procedures are chosen and 290 
employed. Currently, this could be achieved by recruiting more trained personnel as 291 
suggested Bellotti et al.
40
, using transabdominal US combined with transvaginal US, 3D-US, 292 
echocardiography, Doppler, and US markers such as NT
41–42
, ductus venosus blood flow
43–44
, 293 
intracranial translucency
30–31
 or nasal bones
45
. 294 
To conclude, we should remind that the major limitations of this review are due to the 295 
diversity of papers included in it, each one with its intrinsic characteristics. As stated before 296 
the studies included followed their own classifications, some US were not performed exactly 297 
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during the time range 11–13+6 weeks (although, more than 95% were), some studies did not 298 
intended directly to evaluate the performance of first-trimester US as a detection tool, and 299 
most importantly, results were and still are entirely human dependent.  300 
On the other hand, we think that the values presented in our review are valid, in the sense that 301 
they were obtained following a precise and reproducible method, allied to strict criteria, that 302 
took into account the limitations and bias that the included studies could introduce. 303 
Furthermore, all the obtained information was summarized so as to simplify the extraction of 304 
prevalences and sensitivities. 305 
Moreover, this paper emphasize that even if first-trimester US alone is far from 100% 306 
accurate in the diagnosis of fetal malformations it is an approach that must always be taken 307 
into account.  308 
In the future, as more sophisticated equipment will be available, broader knowledge about 309 
fetal development and more sophisticated and credible US markers will be accessible, we 310 
hope that the number of abnormalities detected earlier will increase and the 11
th
 to 14
th
 week 311 
scan will become the first comprehensive anatomic fetal survey. 312 
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Table 1 Criteria of eligibility of studies to include in the systematic review 
 Inclusion criteria  
1. Study design Prospective and retrospective studies or random controlled 
trial, in which screening with 2D US was applied for the 
detection of major malformations. 
2. Study aim To evaluate the sensitivity of first trimester US in detecting 
congenital major malformations. 
3. Screening test TV and/or TA US. 
4. Trimester of 
screening 
First trimester pregnancy (11 to 13
+6
 weeks). 
5. Condition 
screened 
Rationale 
Presence of major malformations, defined in one of the 
EUROCAT subgroups
2
. 
Most papers classify the malformations considering the 
main body systems, or simply present each malformation as 
an isolated identity. The EUROCAT defines subgroups that 
allow a straight correspondence with the body system 
approach of the studies, and for each subgroup, defines 
explicitly the type of malformation. Moreover major 
malformations are ICD coded. 
6. Population 
screened 
 
Rationale 
Unselected population or low risk population. 
Singleton pregnancies or information about the number of 
fetuses under evaluation. 
First-trimester US is intended to be a mass-screening test. If 
high-risk population sample is considered, overestimated 
values are expected. 
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7. Reference 
standard 
 
Rationale 
2D US, TV or TA, performed by a physician or a 
technician, between 11 and 13
+6
 weeks of pregnancy, 
looking for major malformations. 
There is no reference standard on how to perform first-
trimester US. At a minimum, there are guidelines, country 
dependent that are followed by some centres. 
 Exclusion criteria  
  
 
 
 
 
 
Rationale 
Malformations due to aneuploidies. 
Study focused in a specific major malformation. 
Study using other techniques beside 2D US, such as 
ecocardiography or 3D ultrasound to confirm the 
malformation. 
Study using soft or biochemical markers. 
Several studies have proven that the use of markers improve 
the detection rate of US 
Language other than English 
2D= two-dimensional; 3D= tri-dimensional; ICD= international classification of 
diseases; US= ultrasound; TA= transabdominal; TV= transvaginal. 
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Table 2 Criteria for assessment of risk of bias 
1. Selection of participants 
Adequate 
 
 
 
Inadequate 
 
Unclear 
 
 Cohort study in which all eligible women are 
included consecutively or randomly. 
 Random controlled trial in which all eligible 
women are included consecutively or randomly. 
 The study does not meet at least one of the afore-
mentioned criteria. 
 The study is unclear in respect to this issue or part 
of it. 
2. Description of 
population 
Adequate 
 
 
Inadequate 
 
Unclear 
 
 
 The following information must be present: 
unselected population and gestational age between 
11–13+6 weeks (equivalent to 11–14 weeks). 
 The study does not meet at least one of the afore-
mentioned criteria. 
 The study is unclear in respect to this issue or part 
of it. 
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3. Description of 
screening test 
Adequate 
 
 
Inadequate 
 
Unclear 
 
 
 The following information must be present: first-
trimester scan, TA and/or TV US approach, and 
classification of major malformations. 
 The study does not meet at least one of the afore-
mentioned criteria. 
 The study is unclear in respect to this issue or part 
of it. 
4. Follow-up and 
verification 
Adequate 
 
 
 
 
 
 
 
 
Inadequate 
 
Unclear 
 
 
 At least 90% of the participants originally 
subjected to the screening test have a follow-up to 
confirm the malformation diagnosed (autopsy, 
later US, after birth observation, enquiry). 
 Miscarriage, voluntary pregnancy termination and 
neo-natal death are considered legitimate 
exclusions, if no malformation was diagnosed or 
no procedure was accomplished in case of 
malformation diagnose. 
 Less than 90% of the participants originally 
subjected to the screening test had a follow-up. 
 The study is unclear in respect to this issue or part 
of it. 
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5. Analysis of results 
Adequate 
 
 
Inadequate 
 
 Measures of accuracy for major malformations are 
available for the test screen (Sn, Sp, ROC, AUC, 
LR+ and LR-). 
 The Sn of the test screen is not explicitly available 
Adapted from QUADAS
9
 and Pedrosa et al. 2011
10
. 
 
AUC= area under curve; LR= likelihood ratio; ROC= receiver operator characteristic; 
Sn= sensitivity; Sp= specificity; TA= transabdominal; TV= transvaginal; US= 
ultrasound. 
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Table 3 Summary of selected studies 
Study Reference 
Country 
Study 
Design 
Length 
of 
Study
*
 
Type of 
Population n
†
 GA
‡
 Type of US Follow-up 
Abu-Rustum et al., 2010
12
 
Lebanon 
Retrospective 7 Unselected 1370 11–13+6 Mostly TA Pediatric report 
Becker et al., 2006
26
 
Germany 
Prospective 7 Unselected 3094 11–13+6 Mostly TA Hospital database + patient 
enquiry 
Borrell et al., 2011
7
 
Spain 
Review 6 Unselected 36237 11–13+6 — — 
Carvalho et al., 2002
13
 
Brazil 
Prospective 4 Unselected 2853 11–13+6 Mostly TA Hospital database + patient 
enquiry 
Cedergren et al., 2006
14
 
Sweden 
Prospective 2 Unselected 2633 11–13+6 TA Hospital database 
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Study Reference 
Country 
Study 
Design 
Length 
of 
Study
*
 
Type of 
Population n
†
 GA
‡
 Type of US Follow-up 
Chen et al., 2004
27
 
China 
Prospective 3 Women aged 
>35 
1609 12–14 TA + TV Hospital database + patient 
enquiry 
Chen et al., 2008
20
 
China 
RCT 3 ½  Unselected 
 
Control 
3974 
Case 
4282 
 
10–14+6 
 
12–14+6  
Mostly TA 
Hospital database + patient 
enquiry 
Dane et al., 2007
15
 
Turkey 
Prospective 2 Unselected 1290 11–13+6 Mostly TA Hospital database + patient 
enquiry 
Economides et al., 1998
16
 
UK 
Prospective NS Unselected 1632 12–13+6 Mostly TA Hospital database + patient 
enquiry 
Ebrashy et al., 2010
21
 
Egypt 
Prospective 5 Unselected 2876 13–14  Mostly TA NS 
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Study Reference 
Country 
Study 
Design 
Length 
of 
Study
*
 
Type of 
Population n
†
 GA
‡
 Type of US Follow-up 
Grande et al., 2012
6
 
Spain 
Retrospective 8 Unselected 13723 11–13+6 TA + TV Hospital database + patient 
enquiry 
Hafner et al., 1997
25
 
Austria 
Prospective 3 NT screening 4233 10–13 Mostly TA Autopsy report + hospital 
database 
Hernádi et al., 1997
28
 
Hungary 
Prospective 3 Unselected 3991 11–14  TV Autopsy report + pediatric 
report 
Hildebrand et al., 2010
17
 
Sweden 
Prospective 4 ½  Unselected 6692 11–14  TA Autopsy report + hospital 
database 
Öztekin et al., 2010
24
 
Turkey 
Prospective 4 Unselected 1085 11–14  Mostly TA Hospital database + patient 
enquiry 
Saltvedt et al., 2006
22
 
Sweden 
RCT 3 ½  Unselected 18053 12–14  Mostly TA Hospital database + patient 
enquiry 
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Study Reference 
Country 
Study 
Design 
Length 
of 
Study
*
 
Type of 
Population n
†
 GA
‡
 Type of US Follow-up 
Souka et al., 2005
23
 
Greece 
Prospective 1 ½  Unselected 1144 11–14  TA + TV NS 
Syngelaki et al., 2011
8
 
UK 
Prospective 3 ½  Unselected 44859 11–13+6  Mostly TA Hospital database + 
pediatric report 
Review 18 CHD 
screening 
67779 10–16§ — — 
Weiner et al., 2007
18
 
Israel/USA 
Prospective 2 NT screening 1723 10
+3–13+6 Mostly TA NS 
Whitlow et al., 1999
19
 
UK 
Prospective 
cross-
sectional 
NS Unselected 6443 11–14 Mostly TA Hospital database + patient 
enquiry 
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Study Reference 
Country 
Study 
Design 
Length 
of 
Study
*
 
Type of 
Population n
†
 GA
‡
 Type of US Follow-up 
 
*
 Length of study in years. 
†
 Number of fetuses. 
‡
 Gestational age in weeks. 
§
 Only 3 scans performed at 15
th
 week of gestation. 
 
CHD= congenital heart disease; GA= gestational age; NS= not specified; NT= nuchal translucency; RCT= randomized controlled trial; TA= 
transabdominal; TV= transvaginal; US= ultrasound. 
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Table 4 Summary of results for each analyzed series 
Study Reference n** 
Total of 
Malformations 
(Prevalence %) 
Malformations 
Detected by 
First-
Trimester US Sn† 
Abu-Rustum et al., 2010
12
 1370 36 (2.6%) 20 55.6% 
Becker et al., 2006
26
 3094 86 (2.8%) 72 83.7% 
Borrell et al, 2011
7
 36237 494 (1.4%) 143 28.9% 
Carvalho et al., 2002
13
 2823 66 (2.3%) 25 37.9% 
Cedergren et al., 2006
14
 2633 32 (1.2%) 13 40.6% 
Chen et al., 2004
27
 1609 16 (1.0%) 7 43.8% 
Chen et al., 2008
20
 Control 
4149 
Case 
4662 
 
64 (1.5%) 
 
63 (1.4%) 
 
21 
 
30 
 
32.8% 
 
47.6% 
Dane et al., 2007
15
 1290 24 (1.9%) 17 70.8% 
Economides et al., 1998
16
 1632 17 (1.0%) 11 64.7% 
Ebrashy et al., 2010
21
 2876 31 (1.0%) 23 74.2% 
Grande et al., 2012
6
 13723 194 (1.4%) 95 49.0% 
Hafner et al., 1997
25
 4233 56 (1.3%) 7 12.5% 
Hernádi et al., 1997
28
 3991 37 (1.0%) 20 54.1% 
Hildebrand et al., 2010
17
 6692 34 (0.5%) 14 41.2% 
Öztekin et al., 2010
24
 1085 21 (1.9%) 14 66.7% 
Saltvedt et al., 2006
22
 18053 371 (2.1%) 74 19.9% 
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Souka et al., 2005
23
 1148 14 (1.2%) 7 50.0% 
Syngelaki et al., 2011
8
 44859‡‡ 488 (1.1%) 213 43.6% 
67779§§ 1087 (1.6%) 443 40.8% 
Weiner et al., 2007
39
 1723 22 (1.3%) 9 40.9% 
Whitlow et al., 1999
19
 6443 66 (1.0%) 44 66.7% 
Averaged Sensitivity (95% CI) 49.2% (41.1 – 57.3) 
Pooled Sensitivity 40.0% 
 
**
 Number of fetuses. 
††
 Study sensitivity. 
‡‡
 Data from prospective study. 
§§
 Data from literature review. 
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Figure 1 Flowchart of the search strategy and selected studies 
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Figure 2 Assessment of the risk of bias 
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paper is accepted, the Author whom you flag as being the formal Corresponding Author
for the paper will receive an e-mail with a link to an online eCTA form. This will enable the
Corresponding Author to complete the copyright form electronically within ScholarOne
Manuscripts on behalf of all authors on the manuscript. You may preview the copyright
terms and conditions here (http://media.wiley.com/assets/2255/84/ECTA-
A_SAMPLE.pdf).
Proofs
Proofs of accepted articles will be sent to the author for checking. This stage is to be used
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Offprints
Free access to the final PDF offprint of your article will be available via Author Services
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Accepted Articles
'Accepted Articles' have been accepted for publication and undergone full peer review but
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OnlineOpen
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grantees to archive the final version of their article. With OnlineOpen, the author, the
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